Tag Archives: AstraZeneca

Europe: Resisting the Anticompetitive Crusade

By Julian Upton | Published: July 23, 2010
It’s been another rocky few weeks for pharma in Europe. Particularly for big brand name companies. But necessity is proving the mother of invention, says Pharm Exec’s Brussels correspondent, Reflector. AstraZeneca suffered a serious setback at the start of July when the European General Court ruled that it had illegally prevented generic competition. The case dates [...]
Posted in Strategy | Also tagged , , , , , , | Leave a comment

AZ Celebrates Crestor Patent Win

By George Koroneos | Published: June 30, 2010
The US District Court in Delaware upheld AstraZeneca’s patent for its blockbuster statin Crestor (rosuvastatin), ending a dispute that could have crippled the drugmaker’s billion-dollar cash cow. Crestor’s patent is not scheduled to expire until 2016. However, a group of generics firms had claimed that a substance patent (314) protecting one of the active ingredients in [...]
Posted in Legal | Also tagged , , , , , , | Leave a comment

Pharma Digital Smarts Quantified in IQ Index

By Julian Upton | Published: May 26, 2010
Pfizer’s Viagra and AstraZeneca’s (AZ) Nexium took the top two slots on a new Digital IQ Index measuring the digital competence of 51 pharma brands across eight therapeutic categories. The ranking, created by think tank L2 in partnership with media agency PHD Network, evaluated brands’ digital presence across four criteria: platform (including site effectiveness and [...]
Posted in E-Media | Also tagged , , , , , , , , | Leave a comment

A Few Words About Diversification

By Julian Upton | Published: February 1, 2010
Guest blog by Dr Brian White, an analyst at Shore Capital. As a result of the feared impact of the patent expiry cliff, the decimation of branded sales by multi-sourced generics and the obstacles erected, especially by managed care in the US, to slow the uptake of branded pharmaceuticals where a generic in the same class [...]
Posted in Europe, Global, Guest Blog, Strategy | Also tagged , , , , , | Leave a comment

AstraZeneca to Slash 8,000 More Jobs (Updated 2/3/10)

By Oriana Schwindt | Published: January 28, 2010
Last year, AstraZeneca announced the elimination of some 15,000 jobs. Last Thursday, the London-based company revealed that it plans to lay off another 8,000 by 2014—this despite global revenue growth of 4 percent for 2009. Much of the drive for this addition labor sculpting stems from AZ’s desire to streamline its R&D; the company will focus [...]
Posted in Strategy | Also tagged , , , , , , , | 1 Comment